10-Q: Cocrystal Pharma Reports Q1 2025 Results: Focus Remains on Antiviral Development Amidst Financial Uncertainty

Cocrystal Pharma's Q1 2025 results show a reduced net loss compared to the previous year, driven by decreased research and development expenses, but the company expresses concerns about its ability to continue as a going concern without additional funding.

Summary

• Cocrystal Pharma reported a net loss of $2.301 million for the three months ended March 31, 2025, compared to a net loss of $3.956 million for the same period in 2024.
• Research and development expenses decreased by $1.590 million, primarily due to the Influenza CC-42344 product candidate moving out of Phase 2a clinical trial and the finalizing of the Phase 1 clinical trial of norovirus and coronavirus candidate CDI-988.
• General and administrative expenses decreased by $227,000 due to a reduction in insurance cost and other general and administrative expense.
• The company's cash and restricted cash totaled $6.996 million as of March 31, 2025.
• Cocrystal Pharma believes its current resources will not be sufficient to fund operations beyond the next 12 months.
• The company is focusing its research and development efforts on norovirus, coronavirus, and influenza programs.
• A Phase 2a human challenge study with oral CC-42344 for influenza A is ongoing, but enrollment was extended due to a low influenza infection rate among study participants.
• Oral CDI-988 is being clinically evaluated for safety, tolerability, and pharmacokinetics in a Phase 1 study in Australia.
• The company is seeking shareholder approval for a new Equity Incentive Plan (the 2025 Plan) at its annual meeting scheduled for June 25, 2025.
• The company is party to an At-The-Market Offering Agreement, dated July 1, 2020 (ATM Agreement) with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which the Company may issue and sell over time and from time to time, to or through Wainwright, up to $10,000,000 of shares of the Company's common stock.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company has reduced its net loss and is progressing with clinical trials, concerns about its ability to continue as a going concern and the delay in the Phase 2a study weigh heavily on the outlook.

Positives

• The net loss decreased significantly compared to the same period last year.
• Research and development expenses were reduced, indicating potential cost management.
• The company continues to advance its antiviral programs, including CC-42344 and CDI-988, through clinical trials.
• CC-42344 has demonstrated a favorable safety and tolerability profile in the Phase 2a study to date.
• CDI-988 has shown favorable safety and tolerability results in the single-ascending dose (SAD) cohorts of the Phase 1 study.
• The company is developing novel broad-spectrum influenza antivirals targeting replication enzymes of seasonal and pandemic influenza A and B strains.

Negatives

• The company has a history of net losses and negative operating cash flows.
• There are concerns about the company's ability to continue as a going concern without additional funding.
• The Phase 2a study for CC-42344 experienced enrollment delays due to low influenza infection rates.
• The company has not yet established an ongoing source of revenue sufficient to cover its operating costs.
• The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funds.
• Clinical trial delays, such as the one experienced with the CC-42344 Phase 2a study, can impact timelines and increase costs.
• The development of effective treatments and/or vaccines by competitors could negatively impact the company's prospects.
• Potential mutations in viruses targeted by the company's product candidates could lead to resistance.
• The company's future operating costs could become subject to inflationary pressures in the future particularly based upon United States tariff policy, which could have a material effect on increasing the Company's operating costs, and which would put additional stress on the Company's working capital resources.

Future Outlook

The company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases and believes that its current resources will not be sufficient to fund operations beyond the next 12 months.

Management Comments

• Management intends to fund future operations through additional private or public equity offerings and through arrangements with strategic partners or from other sources.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on antiviral therapeutics. The report mentions competitors developing vaccines for norovirus and highlights the competitive landscape for Hepatitis C treatments, indicating the need for innovative and shorter treatment regimens.

Comparison to Industry Standards

• The report mentions competitors developing vaccines for norovirus, including Vaxart Pharmaceutical, Moderna, Hillevax, Takeda Pharmaceuticals, Anhui Zhifei Longcom Biopharmaceutical (China) and National Vaccine and Serum Institute (China).
• For Hepatitis C, the company aims to develop ultra-short combination oral treatments of four to six weeks, while current treatments like Harvoni, Viekira Pak, Epclusa, Zepatier, and Mavyret range from eight to twelve weeks.
• The company is targeting the viral NS5B polymerase with an NNI, which could be developed as part of an all-oral, pan-genotypic combination regimen.

Corporate Governance

Related Party Transactions

• The company leases office space in Miami, Florida from a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the company.
• On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company's financial situation does not improve.
• The company's ability to develop and commercialize antiviral therapeutics could impact patients and the broader healthcare industry.

Next Steps

• The company will continue discussions with the clinical research organization to address the Phase 2a study for CC-42344 and determine a course forward.
• The company expects to release results from the high-dose cohort of the Phase 1 study with CDI-988 in the first half of 2025.
• The company is seeking shareholder approval for the 2025 Equity Incentive Plan at its annual meeting scheduled for June 25, 2025.
• Management intends to fund future operations through additional private or public equity offerings and through arrangements with strategic partners or from other sources.

Key Dates

Keywords

antiviral, clinical trials, research and development, influenza, coronavirus, norovirus, CC-42344, CDI-988, biopharmaceutical, funding, liquidity, net loss